Kane Biotech Inc. reports developments tied to its antimicrobial wound care business, including commercialization of the revyve product line in the United States and Canada. The company is developing and marketing wound care treatments that target biofilms and wound bacteria, with revyve Antimicrobial Wound Gel, revyve Antimicrobial Wound Gel Spray, and revyve Antimicrobial Skin and Wound Cleanser holding U.S. FDA 510(k) clearance; the gel and gel spray are also approved by Health Canada.
Recurring news includes financial results, distribution and sales-agent agreements, regulatory and quality-system updates, and scientific publications or conference presentations involving chronic wound and burn care research. Company updates also discuss operating expenses, continuing operations, and the discontinued animal health contract manufacturing activities that have affected recent results.
Kane Biotech (KNBIF) has engaged Independent Trading Group to provide market-making services, subject to TSX Venture Exchange approval.
ITG will trade Kane common shares on the TSXV and other venues, with the stated objective of maintaining an orderly market and improving liquidity. The fee is $5,000 per month plus applicable taxes. The agreement has an initial one-month term and automatically renews monthly; either party may terminate with at least 30 days’ prior written notice. ITG will receive no performance-based compensation, shares or options. The companies are unrelated and unaffiliated.
Kane Biotech (KNBIF) signed a Canadian distribution agreement with The Stevens Company, effective October 1, 2026, for its revyve wound-care products. The non-exclusive agreement authorizes Stevens to purchase and resell Health Canada-licensed revyve Antimicrobial Wound Gel in 1 oz and 3 oz formats and Antimicrobial Wound Gel Spray in the 5 oz format throughout Canada.
Stevens supplies hospitals, long-term care homes and community healthcare providers across Canada. Kane said the partnership combines its clinical expertise and relationships with Stevens’ sales and distribution network to broaden access to revyve and make the products easier for healthcare providers to source and adopt. The arrangement adds a distribution channel for Kane’s licensed wound-care products in the Canadian market.
Kane Biotech (KNBIF) will showcase revyve at the Wounds Canada National Hybrid Conference, taking place October 22–24, 2026. The event will be held in Niagara Falls, Ontario.
The company will exhibit at Booth 604 and present data during the conference. Its team plans to meet clinicians, educators and other wound-care professionals to discuss biofilm management in clinical practice. The revyve Antimicrobial Wound Gel and Antimicrobial Wound Gel Spray are U.S. FDA 510(k) cleared and Health Canada approved.
Kane Biotech (KNBIF) has launched a redesigned corporate website and refreshed brand identity, including an updated logo and visual identity.
The company said the refresh reflects its evolution as a commercial-stage wound-care business. The website includes sections on biofilm science, proprietary technology platforms, commercial revyve wound-care products, clinical resources and evidence, the product-development pipeline, and corporate and investor information. It also includes clinician and patient perspectives. Kane plans to add further clinical, scientific, product and corporate materials.
Kane Biotech (KNBIF) has accepted a $250,000 unsecured loan from board chair Philip Renaud to support its working capital needs. Renaud is also an approved control person of the company. The loan is non-interest-bearing and repayable on demand, with no bonus paid or payable in connection with it.
Kane intends to use the proceeds for general working capital and corporate purposes and repay the loan from future capital raises or general revenue. The financing is a related party transaction under MI 61-101 and TSX Venture Exchange Policy 5.9. Kane is relying on exemptions from formal valuation and minority shareholder approval requirements because the loan’s fair market value does not exceed 25% of the company’s market capitalization.
Kane Biotech (KNBIF) will showcase revyve and present scientific posters at SAWC Fall, taking place October 15–18, 2026, in Las Vegas.
Dr. Robert Huizinga will present three posters on October 17, from 6:15 p.m. to 7:30 p.m. PDT. Topics include modeled economic effects of moving chronic wounds toward healing, compatibility with hypochlorous acid irrigation and standard wound care, and the relationship between tissue oxygenation changes and wound-area reduction. Kane will host Booth #544 and plans to meet existing and prospective distributors to discuss expanding product awareness and commercial reach in the United States and other markets.
Kane Biotech (KNBIF) will host a virtual Commercial Update webcast on Wednesday, September 16, 2026, at 11:00 a.m. Eastern Time.
The approximately 60-minute event will include presentations from Board Chair Philip Renaud, interim CEO Dr. Robert Huizinga and wound-care surgeon Dr. John C. Lantis, followed by a question-and-answer session. The webcast will review Kane’s progress in building a clinically credible, commercially focused wound-care business and its strategy to drive recurring revenue from its U.S. FDA 510(k) cleared and Health Canada approved revyve antimicrobial wound-care portfolio. A replay will be available on the company’s website after the event.
Kane Biotech (KNBIF) entered a non-exclusive Canadian distribution agreement with Ottawa-based Ontario Medical Supply (OMS) for its revyve antimicrobial wound care products.
OMS will purchase, market and support U.S. FDA 510(k) cleared and Health Canada approved revyve Antimicrobial Wound Gel and revyve Antimicrobial Wound Gel Spray, while Kane provides product training and sales materials. OMS is one of only two authorized distributors and price agreement holders for Ontario Health atHome, which coordinates publicly funded home and community care for more than 680,000 patients and delivered 11.1 million nursing visits in Ontario in 2024–25. Published estimates indicate wound care may account for roughly 40–50% of home-care nursing visits, underscoring a substantial wound care burden. The agreement establishes a framework for ordering, training, customer support, quality management, traceability and complaint reporting, which the company says supports its strategy to expand access to revyve across Canada.
Kane Biotech (OTC:KNBIF, TSX-V:KNE) reported second quarter 2026 revenue of $8,143, down from $27,997 a year earlier, reflecting its transition from legacy animal health and DermaKB lines to early-stage commercialization of its revyve antimicrobial wound care portfolio in Canada and the United States.
Gross profit improved to $1,444 from a gross loss of $(45,526), while operating expenses rose to $785,927 from $229,930, largely due to stock option expense and prior-year compensation reversals. Net loss widened to $(833,636) versus $(348,541), and cash at June 30, 2026 was $854,729, according to Kane Biotech.
Kane Biotech highlighted ongoing commercialization efforts for revyve, including distributor expansion, clinical evaluations at multiple North American sites, a new Scientific Advisory Board, manufacturing scale-up activities, and plans to initiate DispersinB Hydrogel biocompatibility testing in the third quarter of 2026.
Kane Biotech (OTCQB:KNBIF, TSX-V:KNE) reported that research on its revyve antimicrobial wound care technology was presented at the Military Health System Research Symposium (MHSRS), held August 3-5, 2026 in Kissimmee, Florida. The talk addressed potential uses in prolonged field care and military wound management, especially in austere environments where access to advanced medical care may be delayed.
The presentation, titled “Broad-Spectrum, Cavity-Filling Antimicrobial Gel Spray to Address Prolonged Field Care Wound Challenges,” highlighted revyve Antimicrobial Wound Gel Spray, which is U.S. FDA 510(k) cleared and Health Canada approved. According to Kane, clinicians expressed interest in revyve’s antimicrobial, antibiofilm, and cavity-filling properties and its contactless, rapid delivery.
Following MHSRS, several researchers approached Kane to explore revyve in military, prolonged field care, and complex wound settings, and the company is collaborating with them to develop a clinical research plan. Kane continues commercialization of the revyve product portfolio and sees military and government healthcare channels as a potential long-term opportunity.